Comet phase III trial: Sanofi announces a virtual presentation

The Sanofi laboratory, notably a competitor of Roche, has announced that it will hold a virtual scientific session on June 16 (pre-registration required). This will focus on the results of the COMET phase III trial dedicated to alpha glucosidase alpha (experimental enzyme replacement therapy). Sanofi seeks to treat people with the late form of Pompe disease.

For experts and the specialized press

The scientific session offered by Sanofi will be reserved for healthcare professionals as well as the medical press. Doctor Jordi Diaz-Manera will present the test data. Then, a session of questions and answers will be proposed. It will be led by Doctor Alaa Hamed. Dr. Kristina An Haack will also be on hand to provide answers to questions related to the clinical trial and the clinical development program. The organization of this presentation comes after the International Congress on Neuromuscular Diseases (ICNMD) has been postponed. For information, Pompe disease, which affects around 50,000 people worldwide (children and adults), can cause progressive and irreversible muscle damage. In question ? The absence or malfunction of the lysosomal enzyme alpha-glucosidase acid (GAA).

–
–

–